Investigating silver nanoparticles and resiquimod as a local melanoma treatment.

ABSTRACT: Over the last decade, the potential for silver nanoparticles (AgNP) to be used as an anti-melanoma agent has been supported by both in vitro and in vivo evidence. However, an undesirably high concentration of AgNP is often required to achieve an antitumor effect. Therefore a combination treatment that can maintain or improve antitumor efficacy (with lower amounts of AgNP) while also reducing off-target effects is sought. In this study, the combination of AgNP and resiquimod (RSQ: a Toll-like receptor agonist) was investigated and shown to significantly prolong the survival of melanoma-challenged mice when added sequentially. Results from toxicity studies showed that the treatment was non-toxic in mice. Immune cell depletion studies suggested the possible involvement of CD8⁺ T ce

SUBMITTER: Tambunlertchai S 

PROVIDER: S-EPMC10158852 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature